Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Abemaciclib and MK-6482 in advanced renal cell carcinoma
NCT04627064Phase 1Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Dec 2020
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of abemaciclib in clear cell renal cell carcinoma (ccRCC) (2 arms), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Objective Response Rate in Abemaciclib Arm at 3 months, Objective Response Rate in Abemaciclib and MK-6482 Arm and 1 more. Started Dec 2020; status: completed.
02
Drugs
abemaciclib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT04627064.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04627064.